通过液体活检在 SARS-CoV-2 爆发期间加速肿瘤基因分型。
Speeding tumor genotyping during the SARS-CoV-2 outbreak through liquid biopsy.
机构信息
Thoracic Medical Oncology, Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, USA.
出版信息
Cancer. 2020 Sep 15;126(18):4089-4091. doi: 10.1002/cncr.32983. Epub 2020 May 30.
Abstract
This commentary proposes a shift in the current diagnostic workflow for patients with metastatic cancer to incorporate the use of liquid biopsy. This proposal, born in the time of a severe crisis for the health care system, might also be applied when the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) outbreak ends and thereby reduce the turnaround time for results from molecular testing for patients with cancer and increase the number of patients potentially benefiting from highly effective targeted therapies.
摘要
本评论建议改变当前转移性癌症患者的诊断工作流程，纳入液体活检的应用。在医疗保健系统面临严重危机之际提出的这一建议，也可在严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）疫情结束时应用，从而缩短癌症患者分子检测结果的周转时间，并增加更多可能受益于高效靶向治疗的患者数量。
相似文献
1
Speeding tumor genotyping during the SARS-CoV-2 outbreak through liquid biopsy.通过液体活检在 SARS-CoV-2 爆发期间加速肿瘤基因分型。
Cancer. 2020 Sep 15;126(18):4089-4091. doi: 10.1002/cncr.32983. Epub 2020 May 30.
2
COVID-19 "Liquid Biopsy" Could Offer Monitoring, Prognostic Tool.新冠病毒“液体活检”可提供监测和预后工具。
JAMA. 2021 Mar 9;325(10):924. doi: 10.1001/jama.2021.2496.
3
Deep cfDNA fragment end profiling enables cancer detection.深度cfDNA片段末端分析可实现癌症检测。
Mol Cancer. 2022 Jan 21;21(1):26. doi: 10.1186/s12943-021-01491-8.
4
Cell-free DNA diagnostics: current and emerging applications in oncology.无细胞 DNA 诊断学：肿瘤学中的当前和新兴应用。
Pharmacogenomics. 2019 Apr;20(5):357-380. doi: 10.2217/pgs-2018-0174. Epub 2019 Apr 15.
5
Detection of mutational patterns in cell-free DNA of colorectal cancer by custom amplicon sequencing.通过定制扩增子测序检测结直肠癌游离 DNA 中的突变模式。
Mol Oncol. 2019 Aug;13(8):1669-1683. doi: 10.1002/1878-0261.12539. Epub 2019 Jul 19.
6
Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.循环游离核酸和血小板作为液体活检在肺癌患者个性化治疗中的应用
Lung Cancer. 2017 May;107:100-107. doi: 10.1016/j.lungcan.2016.04.026. Epub 2016 May 4.
7
Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma.使用血浆 ctDNA、参考标准品和源自正常血浆的合成系列稀释样本，对一种商用的下一代测序液体活检平台进行分析性能评估。
BMC Cancer. 2020 Oct 1;20(1):945. doi: 10.1186/s12885-020-07445-5.
8
Clinical utility of cell-free DNA liquid biopsies in Merkel cell carcinoma.游离DNA液体活检在默克尔细胞癌中的临床应用
Dermatol Online J. 2021 Oct 15;27(10). doi: 10.5070/D3271055629.
9
Liquid biopsies: DNA methylation analyses in circulating cell-free DNA.液体活检：循环无细胞 DNA 中的 DNA 甲基化分析。
J Genet Genomics. 2018 Apr 20;45(4):185-192. doi: 10.1016/j.jgg.2018.02.007. Epub 2018 Mar 8.
10
From cfDNA to Sequencing: Workflows and Potentials.从游离DNA到测序：工作流程与潜力
Methods Mol Biol. 2019;1909:119-125. doi: 10.1007/978-1-4939-8973-7_9.
引用本文的文献
1
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.晚期非小细胞肺癌中循环肿瘤DNA引导治疗的总生存期
Nat Med. 2022 Nov;28(11):2353-2363. doi: 10.1038/s41591-022-02047-z. Epub 2022 Nov 10.
2
Biofluids manipulation methods for liquid biopsy in minimally-invasive assays.用于微创检测中液体活检的生物流体处理方法
MethodsX. 2022 Jun 17;9:101759. doi: 10.1016/j.mex.2022.101759. eCollection 2022.
3
A narrative review on the implementation of liquid biopsy as a diagnostic tool in thoracic tumors during the COVID-19 pandemic.关于在2019冠状病毒病大流行期间将液体活检作为胸部肿瘤诊断工具的实施情况的叙述性综述。
Mediastinum. 2021 Sep 25;5:27. doi: 10.21037/med-21-9. eCollection 2021.
本文引用的文献
1
Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.InVisionFirst-Lung循环肿瘤DNA检测用于晚期非鳞状非小细胞肺癌患者分子谱分析的前瞻性临床验证
JCO Precis Oncol. 2019 Apr 25;3. doi: 10.1200/PO.18.00299. eCollection 2019.
2
Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands.荷兰在新冠疫情期间癌症诊断病例减少。
Lancet Oncol. 2020 Jun;21(6):750-751. doi: 10.1016/S1470-2045(20)30265-5. Epub 2020 Apr 30.
3
Adapting to a Pandemic - Conducting Oncology Trials during the SARS-CoV-2 Pandemic.适应大流行——在 SARS-CoV-2 大流行期间开展肿瘤学试验。
Clin Cancer Res. 2020 Jul 1;26(13):3100-3103. doi: 10.1158/1078-0432.CCR-20-1364. Epub 2020 Apr 20.
4
Safety at the Time of the COVID-19 Pandemic: How to Keep our Oncology Patients and Healthcare Workers Safe.2019年冠状病毒病大流行期间的安全：如何保障我们的肿瘤患者和医护人员的安全。
J Natl Compr Canc Netw. 2020 Apr 15:1-6. doi: 10.6004/jnccn.2020.7572.
5
Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic.癌症、COVID-19 和预防原则：在全球大流行期间优先考虑治疗。
Nat Rev Clin Oncol. 2020 May;17(5):268-270. doi: 10.1038/s41571-020-0362-6.
6
SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China.SARS-CoV-2 在武汉一家三级医院癌症患者中的传播。
JAMA Oncol. 2020 Jul 1;6(7):1108-1110. doi: 10.1001/jamaoncol.2020.0980.
7
Managing COVID-19 in the oncology clinic and avoiding the distraction effect.肿瘤诊所中新冠病毒病的管理及避免干扰效应
Ann Oncol. 2020 May;31(5):553-555. doi: 10.1016/j.annonc.2020.03.286. Epub 2020 Mar 19.
8
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.新型冠状病毒肺炎（SARS-CoV-2）感染的癌症患者：一项中国全国性分析。
Lancet Oncol. 2020 Mar;21(3):335-337. doi: 10.1016/S1470-2045(20)30096-6. Epub 2020 Feb 14.
9
Liquid biopsy as a follow-up tool: Comment on longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors.液体活检作为一种随访工具：关于表皮生长因子受体-酪氨酸激酶抑制剂治疗期间循环游离DNA中体细胞基因改变的纵向监测的评论
Cancer. 2020 Jan 1;126(1):22-25. doi: 10.1002/cncr.32482. Epub 2019 Sep 10.
10
Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer.阿培利司治疗 - 突变型、激素受体阳性晚期乳腺癌。
N Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904.
Zotero 插件